CASTLE BIOSCIENCES INC Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Castle Biosciences Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q4 2024.
  • Castle Biosciences Inc Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $11.4M, a 3.08% decline year-over-year.
  • Castle Biosciences Inc Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $50.3M, a 1.76% decline year-over-year.
  • Castle Biosciences Inc annual Share-based Payment Arrangement, Expense for 2024 was $50.3M, a 1.76% decline from 2023.
  • Castle Biosciences Inc annual Share-based Payment Arrangement, Expense for 2023 was $51.2M, a 41% increase from 2022.
  • Castle Biosciences Inc annual Share-based Payment Arrangement, Expense for 2022 was $36.3M, a 67.1% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $50.3M $11.4M -$363K -3.08% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $50.7M $13M -$16K -0.12% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $50.7M $13.2M +$330K +2.57% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $50.4M $12.7M -$850K -6.29% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $51.2M $11.8M +$1.88M +18.9% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $49.3M $13M +$3.85M +41.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $45.5M $12.8M +$4.07M +46.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $41.4M $13.5M +$5.11M +60.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $36.3M $9.92M +$3.07M +44.8% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $33.2M $9.2M +$3.99M +76.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $29.3M $8.78M +$4.02M +84.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $25.2M $8.42M +$3.51M +71.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $21.7M $6.85M +$3.89M +131% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $17.9M $5.21M +$3.09M +146% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $14.8M $4.77M +$3.11M +188% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $11.6M $4.91M +$3.34M +212% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $8.31M $2.96M +$2.25M +315% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 $6.06M $2.12M +$1.89M +825% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $4.17M $1.65M +$1.51M +1089% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $2.66M $1.58M +$1.41M +839% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.25M $713K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 $229K +$155K +208% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $139K +$54.4K +64.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $168K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q3 2018 $74.4K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $84.6K Apr 1, 2018 Jun 30, 2018 10-Q 2019-09-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.